Royalty pharma plc RPRX 深 沪
已收盘 10-31 16:00:00 美东时间
37.54
+0.600
+1.62%
华盛通- 最 高37.615
- 今 开36.83
- 成交量 377.26万股
- 最 低 36.67
- 昨 收 36.94
- 总市值 158.04亿
- 52周最高 37.78
- 市盈率 静 19.63
- 换手率 0.90%
- 52周最低 23.39
- 委 比 64.42%
- 总股本 4.21亿
- 历史最高 52.46
- 量 比 1.69
- 振 幅 2.56%
- 历史最低 23.39
- 每 手 1
- 风险率 3.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
Agios Pharmaceuticals reported Q3 2025 financial results and updates, highlighting $12.9 million net revenue for PYRUKYND® (mitapivat), an increase of 44% YoY. The FDA extended the PDUFA goal date for PYRUKYND's sNDA in thalassemia to December 7, 2025, due to a request for a REMS program. The CHMP adopted a positive opinion for PYRUKYND in thalassemia, with an EC decision expected by early 2026. Topline RISE UP Phase 3 trial results in sickle cel...
10-30 10:30
Royalty Pharma declares $0.22 dividend
Royalty Pharma (NASDAQ:RPRX) declares $0.22/share quarterly dividend, in line with previous. Forward yield 2.42% Payable Dec. 10; for shareholders of record Nov. 14; ex-div Nov. 14. See RPRX Dividend ...
10-17 20:23
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
Morgan Stanley Maintains Overweight on Royalty Pharma, Lowers Price Target to $54
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and lowers the price target from $55 to $54.
10-11 01:40
Zenas BioPharma rises after Wedbush raises price target
Shares of Zenas BioPharma (NASDAQ:ZBIO) rose on Thursday after Wedbush raised its price target, pointing to the company’s expanding late-stage pipeline and successful asset in-licensing strategy. The ...
10-10 02:20
Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug
Zenas BioPharma secures global rights to orelabrutinib in multiple sclerosis, expands autoimmune pipeline, and raises $120 million in private placement.
10-09 01:56
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Goldman Sachs Initiates Coverage On Royalty Pharma with Buy Rating, Announces Price Target of $42
Goldman Sachs analyst Asad Haider initiates coverage on Royalty Pharma (NASDAQ:RPRX) with a Buy rating and announces Price Target of $42.
09-30 21:03
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
Royalty Pharma announced Dr. Ted W. Love as Lead Independent Director. With extensive biopharma experience, Love will continue to Chair the Nominating and Corporate Governance Committee. Love has served as BIO's Immediate Past Chairman and previously led Global Blood Therapeutics and Onyx Pharmaceuticals. Royalty Pharma, the largest biopharma royalties purchaser, aims to accelerate life sciences innovation. Royalty Pharma has assembled a portfol...
09-29 12:15
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
Royalty Pharma will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on September 23, 2025. The event will be webcast and available for viewing on Royalty Pharma’s website for at least 30 days. Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry. Their portfolio includes royalties on over 35 commercial products and 17 dev...
09-19 20:25
